Skip to main content

Table 1 Subject characteristics according to progression and amyloid status

From: Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment

Characteristic All subjects (n = 276) Amyloid negative (n = 116) Amyloid positive (n = 160)
Stable Progression Stable Progression Stable Progression
Number of subjects 154 (56) 122 (44) 93 (80) 23 (20) 61 (38) 99 (62)
Age (years) 65.5 ± 7.7 68.3 ± 8.1* 63.8 ± 7.9 68.2 ± 8.7 68.2 ± 6.5 68.3 ± 8.0
Male gender 97 (63) 67 (56) 64 (69) 16 (70) 33 (54) 51 (51)
Education 5.0 ± 1.5 4.9 ± 1.7 4.8 ± 1.7 5.0 ± 1.6 5.3 ± 1.2 4.9 ± 1.7
MMSE 27.0 ± 2.2 26.1 ± 2.6* 27.0 ± 2.2 26.6 ± 2.5 27.0 ± 2.2 26.0 ± 2.6
CSF Aβ1–42 794 ± 307 534 ± 194* 999 ± 207 848 ± 172* 481 ± 104 462 ± 107
WMH (Fazekas) 0.99 ± 0.92 1.03 ± 0.80 0.88 ± 0.93 1.30 ± 1.02 1.15 ± 0.89 0.97 ± 0.73
NGMV 0.41 ± 0.04 0.39 ± 0.05* 0.42 ± 0.04 0.39 ± 0.06* 0.41 ± 0.04 0.39 ± 0.04
Follow-up (years) 2.5 ± 1.5 2.6 ± 1.7 2.3 ± 1.4 2.8 ± 2.0 2.7 ± 1.7 2.6 ± 1.3
Follow-up diagnosis
 AD 104 (85) 10 (43) 94 (95)
 DLB 3 (2) 2 (9) 1 (1)
 FTD 4 (3) 3 (13) 1 (1)
 VaD and mixed 9 (7) 6 (26) 3 (3)
 Other 2 (2) 2 (9) 0 (0)
  1. Data presented as mean ± SD or count (%)
  2. AD Alzheimer’s disease, CSF cerebrospinal fluid, DLB Lewy body dementia, FTD fronto-temporal dementia, MMSE Mini-Mental state examination, NGMV normalized gray matter volume, VaD vascular dementia, WMH white matter hyperintensities measured with 4-point Fazekas scale
  3. *p < 0.01 different from stable subjects
  4. p < 0.05 different from stable subjects